APELLIS PHARMACEUTICALS INC. - COMMON STOCK

Apellis Announces Submission of New Drug Application to the FDA for Pegcetacoplan for Geographic Atrophy

01 يونيو 2022 07:00:01 بحسب Nasdaq GlobeNewswire

Apellis Announces Seven Abstracts in PNH to be Presented at the European Hematology Association Congress

12 مايو 2022 11:05:00 بحسب Nasdaq GlobeNewswire

Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

06 مايو 2022 16:23:03 بحسب Nasdaq GlobeNewswire

Apellis Pharmaceuticals to Present at the Bank of America Securities 2022 Healthcare Conference

05 مايو 2022 16:05:04 بحسب Nasdaq GlobeNewswire

Apellis Pharmaceuticals Reports First Quarter 2022 Financial Results

04 مايو 2022 16:05:03 بحسب Nasdaq GlobeNewswire

Apellis Announces Dr. Peter Hillmen, Renowned Hematologist and PNH Expert, to Join Company

03 مايو 2022 07:00:01 بحسب Nasdaq GlobeNewswire

Apellis Announces Detailed 18-Month Results from Phase 3 DERBY and OAKS Studies of Pegcetacoplan for Geographic Atrophy (GA) at ARVO Annual Meeting

02 مايو 2022 15:30:00 بحسب Nasdaq GlobeNewswire

Apellis Pharmaceuticals to Host Conference Call on May 4, 2022 to Discuss First Quarter 2022 Financial Results

26 أبريل 2022 07:00:01 بحسب Nasdaq GlobeNewswire

Apellis Announces Results from New Global Survey Conducted by The Harris Poll Revealing the Emotional Burden and Impact on Independence Caused by Geographic Atrophy (GA)

21 أبريل 2022 07:00:02 بحسب Nasdaq GlobeNewswire

Apellis Pharmaceuticals to Present at the 21st Annual Needham Virtual Healthcare Conference

04 أبريل 2022 07:00:01 بحسب Nasdaq GlobeNewswire

Apellis Pharmaceuticals Announces Closing of Public Offering of Common Stock and Full Exercise of Option to Purchase Additional Shares

28 مارس 2022 16:01:00 بحسب Nasdaq GlobeNewswire

Apellis Pharmaceuticals Announces Pricing of Public Offering of Common Stock

24 مارس 2022 07:00:01 بحسب Nasdaq GlobeNewswire

Apellis Pharmaceuticals Announces Proposed Public Offering of Common Stock

23 مارس 2022 16:02:57 بحسب Nasdaq GlobeNewswire

Apellis Announces Pegcetacoplan Showed Continuous and Clinically Meaningful Effects at Month 18 in Phase 3 DERBY and OAKS Studies for Geographic Atrophy (GA)

16 مارس 2022 07:00:00 بحسب Nasdaq GlobeNewswire

Apellis Pharmaceuticals to Present at Upcoming Investor Conferences

02 مارس 2022 07:00:01 بحسب Nasdaq GlobeNewswire

Apellis Pharmaceuticals Reports Fourth Quarter and Full Year 2021 Financial Results

28 فبراير 2022 16:05:01 بحسب Nasdaq GlobeNewswire

Apellis Pharmaceuticals to Host Conference Call on February 28, 2022 to Discuss Fourth Quarter and Full Year 2021 Financial Results

22 فبراير 2022 07:00:01 بحسب Nasdaq GlobeNewswire

Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

06 يناير 2022 16:05:00 بحسب Nasdaq GlobeNewswire

Apellis Pharmaceuticals to Present at the 40th Annual J.P. Morgan Healthcare Conference

03 يناير 2022 07:00:00 بحسب Nasdaq GlobeNewswire

Apellis and Sobi Announce EU Approval of Aspaveli® (pegcetacoplan) for Treatment of PNH

15 ديسمبر 2021 07:00:00 بحسب Nasdaq GlobeNewswire